Cellectis (CLLS) Current Deferred Revenue (2016 - 2026)
Cellectis' (CLLS) quarterly Current Deferred Revenue came in at $93.1 million in Q1 2026, down 17.87% year-on-year from $113.3 million in Q1 2025, and down 3.86% quarter-over-quarter from $96.8 million in Q4 2025.
Cellectis (CLLS) Current Deferred Revenue (2016 - 2026) Analysis & Trends
Cellectis' Current Deferred Revenue history runs 11 years deep, the most recent figure standing at $93.1 million for Q1 2026.
- On a quarterly basis, Current Deferred Revenue fell 17.87% year-over-year to $93.1 million in Q1 2026; TTM through Mar 2026 was $93.1 million, a 17.87% decrease from a year earlier, with the FY2025 full-year figure at $96.8 million, down 13.69% from the prior year.
- Current Deferred Revenue retreated to $93.1 million in Q1 2026 per CLLS's latest filing, from $96.8 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $122.0 million in Q3 2024 and bottomed at $59000.0 in Q4 2022.
- The 5-year median for Current Deferred Revenue is $94.0 million (2025), against an average of $64.4 million.
- Across the five-year window, Current Deferred Revenue slumped 80.4% in 2022 and jumped 186891.53% in 2023, its largest moves.
- Year by year, Current Deferred Revenue stood at $59000.0 in 2022, then soared by 186891.53% to $110.3 million in 2023, then increased by 1.66% to $112.2 million in 2024, then slipped by 13.69% to $96.8 million in 2025, then fell by 3.86% to $93.1 million in 2026.
- Per Business Quant, the three latest CLLS Current Deferred Revenue figures stand at $93.1 million (Q1 2026), $96.8 million (Q4 2025), and $94.0 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Cellectis | 281.48 Mn | 95.81 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 93.06 Mn |
| Dec 31, 2025 | 96.80 Mn |
| Sep 30, 2025 | 94.01 Mn |
| Jun 30, 2025 | 113.38 Mn |
| Mar 31, 2025 | 113.30 Mn |
| Dec 31, 2024 | 112.16 Mn |
| Sep 30, 2024 | 122.01 Mn |
| Jun 30, 2024 | 117.75 Mn |
| Mar 31, 2024 | 120.56 Mn |
| Dec 31, 2023 | 110.33 Mn |
| Sep 30, 2023 | 117,000.00 |
| Jun 30, 2023 | 241,000.00 |
| Mar 31, 2023 | 342,000.00 |
| Dec 31, 2022 | 59,000.00 |
| Sep 30, 2022 | 320,000.00 |
| Jun 30, 2022 | 400,000.00 |
| Mar 31, 2022 | 581,000.00 |
| Dec 31, 2021 | 301,000.00 |
| Sep 30, 2021 | 500,000.00 |
| Jun 30, 2021 | 423,000.00 |